Omeros
About OmerosPipelineInvestorsNews


2018 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
07/17/18Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction
-- Nicotine Addiction Planned as First Indication -- SEATTLE--(BUSINESS WIRE)--Jul. 17, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros’ OMS527 program broadly targeting addictions and compulsive disorders. Inhibitors of PDE7 have been demonstrated to modulate the brain’s ... 
 Printer Friendly Version
06/27/18Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
– First Clinical Target for PDE7 Inhibitor to be Nicotine Addiction – SEATTLE--(BUSINESS WIRE)--Jun. 27, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead phosphodiesterase 7 (PDE7) inhibitor from the company’s OMS527 program. Omeros discovered the link between PDE7 and addiction, and the company holds broad patents ... 
 Printer Friendly Version
05/24/18Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin
--Lupin Confirms Validity of OMIDRIA Patents-- SEATTLE--(BUSINESS WIRE)--May 24, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (Lupin), resolving Omeros’ patent litigation against Lupin. The litigation concerned Lupin’s filing of an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Adminis... 
 Printer Friendly Version
05/10/18Omeros Corporation Reports First Quarter 2018 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE--(BUSINESS WIRE)--May 10, 2018-- Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018, which include: 1Q 2018 total and OMIDRIA® revenues were $1.6 million, compared to $12.3 million in 1Q 2017; the decrease is the result of the scheduled expiration of OMIDRIA pass-throu... 
 Printer Friendly Version
05/07/18Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018
SEATTLE--(BUSINESS WIRE)--May 7, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its first quarter 2018 financial results for the period ended March 31, 2018, on Thursday, May 10, 2018, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. Conference Call Details To a... 
 Printer Friendly Version
04/26/18FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
– Discussions Ongoing with FDA and European Regulators for Expedited Approval – SEATTLE--(BUSINESS WIRE)--Apr. 26, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), specifically those patients who have pers... 
 Printer Friendly Version
04/19/18Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting
--OMIDRIA demonstrates clear benefits across traditional and femtosecond laser-assisted cataract surgery and in IFIS cases-- SEATTLE--(BUSINESS WIRE)--Apr. 19, 2018-- Omeros Corporation (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and A... 
 Printer Friendly Version
04/13/18Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
SEATTLE--(BUSINESS WIRE)--Apr. 13, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Congress in Washington, D.C., April 13-17, 2018. The four presentations are scheduled as follows: Saturday, April 14: 1:41... 
 Printer Friendly Version
04/12/18OMIDRIA® Added to Veterans Health Administration National Formulary
-- OMIDRIA now available across the VA system to benefit U.S. veterans -- SEATTLE--(BUSINESS WIRE)--Apr. 12, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that the Veterans Administration (VA) has added OMIDRIA® (phenylephrine and ketorolac intraocular solution 1% / 0.3%) to the VA National Formulary. The VA National Formulary is a listing of drugs and supplies that must be available at all VA facilities for the benefit of U.S. mili... 
 Printer Friendly Version
04/11/18Omeros Announces Amendment of Credit Facility
SEATTLE--(BUSINESS WIRE)--Apr. 11, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP, a healthcare-focused investment firm. With respect to the twelve-month period beginning on January 1, 2018, the amendment deems Omeros to have met the financial covenants requiring the company to achieve a minimum net revenue or market capitalization amount. Th... 
 Printer Friendly Version
03/01/18Omeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results
Conference Call Today at 4:30 p.m. ET SEATTLE--(BUSINESS WIRE)--Mar. 1, 2018-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced recent highlights and developm... 
 Printer Friendly Version
02/26/18Omeros Corporation to Announce Fourth Quarter and Year-End 2017 Financial Results on March 1, 2018
SEATTLE--(BUSINESS WIRE)--Feb. 26, 2018-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2017 financial results for the period ended December 31, 2017, on Thursday, March 1, 2018, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. Conference Call Details... 
 Printer Friendly Version
02/15/18Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
-- Greater than 16-Fold Improvement in Survival Compared to Historical Control -- SEATTLE--(BUSINESS WIRE)--Feb. 15, 2018-- Omeros Corporation (NASDAQ: OMER) today announced new results from the company’s ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA). The data demonstrate an increase in median overall survival in HCT-TMA patients treated with OMS721 c... 
 Printer Friendly Version
01/22/18European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros’ OMS721 in the Treatment of IgA Nephropathy
-- EMA also reviewing Priority Medicines application for the drug in IgAN -- SEATTLE--(BUSINESS WIRE)--Jan. 22, 2018-- Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Omeros’ application for orphan drug designation of OMS721 in the treatment of primary Immunoglobulin A nephropathy (IgAN). OMS721 is Omeros’ lead human monoc... 
 Printer Friendly Version
01/03/18Omeros Corporation Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy
-- Also Initiates OMS721 Phase 3 Program in HCT-TMA -- SEATTLE--(BUSINESS WIRE)--Jan. 3, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has reached agreement with the US Food and Drug Administration (FDA) on Omeros’ protocol for its Phase 3 clinical trial evaluating OMS721 in patients with IgA nephropathy (IgAN). Patient enrollment is expected to begin early next month. The single Phase 3 trial is a randomized, double... 
 Printer Friendly Version